Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

por Prado, C M M, Bekaii-Saab, T, Doyle, L A, Shrestha, S, Ghosh, S, Baracos, V E, Sawyer, M B
Publicado 2012